All In Biotech

Drug Trial Radar · NCT05207787

Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10365 in Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

306

Planned (sponsor's estimate)

Start

Nov 9, 2021

Primary completion

Apr 30, 2024

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor patients.

Conditions

  • Solid Tumor

Interventions

  • HS-10365Drug

    Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To determine the maximum tolerated dose (MTD) or maximum administrated dose(MAD)Time frame: Up to 28 days.
  2. Phase 2: Response Rate (ORR) assessed by independent review committee (IRC)Time frame: From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study, whichever came first, up to 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.